TY - JOUR
T1 - Predictive factors of histologic response to primary chemotherapy in patients with ewing sarcoma
AU - Ferrari, Stefano
AU - Bertoni, Franco
AU - Palmerini, Emanuela
AU - Errani, Costantino
AU - Bacchini, Patrizia
AU - Pignotti, Elettra
AU - Mercuri, Mario
AU - Longhi, Alessandra
AU - Cesari, Marilena
AU - Picci, Piero
PY - 2007/6
Y1 - 2007/6
N2 - A correlation between chemotherapy-induced necrosis and prognosis has been reported in Ewing sarcoma. To identify factors influencing histologic response data from 122 patients with Ewing sarcoma surgically treated were reviewed. Primary chemotherapy was based on vincristine, doxorubicin, cyclophosphamide, ifosfamide, actinomycin-D, and etoposide. Patients with complete necrosis or only scattered foci of viable tumor cells were good responders (GRs), the remaining patients poor responders (PRs). Age, sex, site and size of the tumor, fever at diagnosis, and lactate dehydrogenase level were clinical variables investigated. Mean age was 13.3±6 in GR and 18.1±9 in PR (P18 years (P=0.003). Female were more likely to achieve a GR (F 64% vs. M 42%, P
AB - A correlation between chemotherapy-induced necrosis and prognosis has been reported in Ewing sarcoma. To identify factors influencing histologic response data from 122 patients with Ewing sarcoma surgically treated were reviewed. Primary chemotherapy was based on vincristine, doxorubicin, cyclophosphamide, ifosfamide, actinomycin-D, and etoposide. Patients with complete necrosis or only scattered foci of viable tumor cells were good responders (GRs), the remaining patients poor responders (PRs). Age, sex, site and size of the tumor, fever at diagnosis, and lactate dehydrogenase level were clinical variables investigated. Mean age was 13.3±6 in GR and 18.1±9 in PR (P18 years (P=0.003). Female were more likely to achieve a GR (F 64% vs. M 42%, P
KW - Age
KW - Chemotherapy
KW - Ewing sarcoma
KW - Necrosis
KW - Sex
UR - http://www.scopus.com/inward/record.url?scp=34250004610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250004610&partnerID=8YFLogxK
U2 - 10.1097/MPH.0b013e3180640d08
DO - 10.1097/MPH.0b013e3180640d08
M3 - Article
C2 - 17551396
AN - SCOPUS:34250004610
VL - 29
SP - 364
EP - 368
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
SN - 1077-4114
IS - 6
ER -